Credit Suisse Group AG Reiterates “Underperform” Rating for AstraZeneca plc (AZN)
AstraZeneca plc (LON:AZN)‘s stock had its “underperform” rating restated by stock analysts at Credit Suisse Group AG in a research note issued on Friday. They presently have a GBX 4,000 ($52.21) price target on the biopharmaceutical company’s stock. Credit Suisse Group AG’s target price suggests a potential downside of 20.41% from the company’s current price.
Other research analysts have also recently issued reports about the company. Deutsche Bank AG reiterated a “buy” rating and issued a GBX 5,800 ($75.71) price target on shares of AstraZeneca plc in a research note on Friday, July 29th. Berenberg Bank set a GBX 5,550 ($72.44) price target on AstraZeneca plc and gave the company a “buy” rating in a research note on Thursday, August 25th. HSBC reiterated a “hold” rating and issued a GBX 4,240 ($55.35) price target on shares of AstraZeneca plc in a research note on Friday, June 17th. Citigroup Inc. reiterated a “buy” rating on shares of AstraZeneca plc in a research note on Wednesday, July 27th. Finally, Goldman Sachs Group Inc. set a GBX 4,000 ($52.21) price target on AstraZeneca plc and gave the company a “sell” rating in a research note on Wednesday, August 10th. Five investment analysts have rated the stock with a sell rating, fourteen have given a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of GBX 4,937.91 ($64.46).
AstraZeneca plc (LON:AZN) opened at 5026.00 on Friday. The company’s market capitalization is GBX 63.58 billion. The firm’s 50-day moving average price is GBX 5,004.64 and its 200 day moving average price is GBX 4,431.30. AstraZeneca plc has a 12-month low of GBX 3,680.00 and a 12-month high of GBX 5,505.00.
The firm also recently declared a dividend, which was paid on Monday, September 12th. Investors of record on Thursday, August 11th were given a GBX 68.70 ($0.90) dividend. The ex-dividend date of this dividend was Thursday, August 11th. This represents a yield of 1.37%.
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Stock Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related stocks with our FREE daily email newsletter.